$0.04
12.47% yesterday
Nasdaq, May 20, 09:14 pm CET
ISIN
US92731L1061
Symbol
VINC
Sector
Industry

Vincerx Pharma Inc Stock price

$0.04
-0.09 68.42% 1M
-5.47 99.24% 6M
-5.21 99.20% YTD
-13.61 99.69% 1Y
-35.36 99.88% 3Y
-186.96 99.98% 5Y
-186.96 99.98% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.01 12.47%
ISIN
US92731L1061
Symbol
VINC
Sector
Industry

Key metrics

Market capitalization $220.00k
Enterprise Value $-4.30m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF 0.19
P/B ratio (TTM) P/B ratio 0.11
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-27.32m
Free Cash Flow (TTM) Free Cash Flow $-22.84m
Cash position $4.52m
EPS (TTM) EPS $-9.34
Short interest 2.72%
Show more

Is Vincerx Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Vincerx Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Vincerx Pharma Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Vincerx Pharma Inc:

Buy
100%

Financial data from Vincerx Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.83 0.83
19% 19%
-
-0.83 -0.83
19% 19%
-
- Selling and Administrative Expenses 15 15
32% 32%
-
- Research and Development Expense 11 11
49% 49%
-
-26 -26
22% 22%
-
- Depreciation and Amortization 0.83 0.83
19% 19%
-
EBIT (Operating Income) EBIT -27 -27
22% 22%
-
Net Profit -23 -23
41% 41%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vincerx Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vincerx Pharma Inc Stock News

Neutral
GlobeNewsWire
about one month ago
Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025
Neutral
GlobeNewsWire
about one month ago
SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger.
Neutral
GlobeNewsWire
2 months ago
SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and Q...
More Vincerx Pharma Inc News

Company Profile

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed Hamdy, Raquel Izumi, Tom Thomas, Stuart Hwang, and John Byrd in 2018 and is headquartered in Palo Alto, CA.

Head office United States
CEO Ahmed Hamdy
Employees 13
Founded 2018
Website vincerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today